Core Viewpoint - Eli Lilly's experimental weight-loss pill may receive expedited approval from the U.S. Food and Drug Administration (FDA) through a one- to two-month review process, according to several Wall Street analysts [1] Company Summary - Eli Lilly is currently in the process of developing a weight-loss pill that has shown promise in clinical trials [1] - The potential fast-tracking of the approval process could significantly impact Eli Lilly's market position and revenue streams in the weight-loss sector [1] Industry Summary - The FDA's new review process aims to accelerate the approval of drugs that could address significant health issues, such as obesity [1] - Analysts suggest that the expedited review could lead to increased competition in the weight-loss drug market, influencing pricing and market dynamics [1]